Company: Tasly Pharmaceutical Group Company Limited

Bloomberg ticker: 600535 SH

Market cap: US$3,339m

Background: Tasly Pharmaceutical Group Company Limited focuses on research, development, manufacturing, and marketing of modern traditional Chinese medicine (TCM) and chemical drugs. Operating primarily in China with a growing international presence, its flagship product, Dantonic, is a cardiovascular TCM drug.
 

World Class Benchmarking of Tasly Pharmaceutical Group
 

(Click on image to enlarge)

• Profitable Growth rank of 6 was down compared to the prior period’s 5th rank
• This is below average performance compared to 380 large Health Care companies worldwide
• Profitability rank of 5 was better than its Growth rank of 8
• Profitability rank of 5 was down compared to the prior period’s 4th rank
• This is average performance compared to peers
• Growth rank of 8 was down compared to the prior period’s 6th rank
• This is below average performance compared to peers

More By This Author:

Stock Analysis: GFPT Public Company Limited
Stock Analysis: Tong Yang Industry
Stock Analysis: DigiPlus Interactive Corp.